Acquisition expands Day One's portfolio with novel antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) Emi-Le has demonstrated early anti-tumor activity in an ongoing Phase 1 study for adenoid ...
Volato Group, Inc. (NYSE American: SOAR) ("Volato" or the "Company") today announced financial results for the quarter ended September 30, 2025, reporting its third consecutive quarterly profit, ...
Technology-driven critical metals company advancing Western supply resistance through patented processing IP, strategic exploration assets, and global business opportunities. Highlights 1,000m of HQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback